Utility and limitations of the FDA adverse events reporting system public dashboard for safety analyses: a case study with vesicular monoamine transporter 2 inhibitors

Expert Opinion on Drug Safety · Published 2025-11-10 · DOI 10.1080/14740338.2025.2588634

Authors being retrieved — see the publisher record. https://doi.org/10.1080/14740338.2025.2588634

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2025

Related articles

Distribution and Characteristics of Vaccine Adverse Events: Analysis of Over 2 Million Individual Case Safety Reports · Hospital Pharmacy · 2026 · Cites or is cited by this article
Possible Signals of Ocular Disorders Associated with Gabapentinoids: A Three-Arm Study · PHARMACEUTICALS · 2026 · Cites or is cited by this article
Hepatic Safety of Ketamine and Esketamine for Treatment-Resistant Depression · Journal of Clinical Psychopharmacology · 2026 · Cites or is cited by this article
Comparison of ciprofol and propofol on dreaming and emotional response during painless gastroscopy: a single-center randomized controlled trial · Expert Opinion on Drug Safety · 2025 · Same journal
Rare irAEs associated with immune checkpoint inhibitor therapy · Expert Opinion on Drug Safety · 2026 · Same journal
Safety and optimal use of direct oral anticoagulant therapy · Expert Opinion on Drug Safety · 2025 · Same journal
Safe prescribing of antihypertensive drugs in the elderly and managing the risk of adverse events · Expert Opinion on Drug Safety · 2026 · Same journal
Safety of anti-IL-5 compounds for the treatment of eosinophilic asthma with a focus on special populations · Expert Opinion on Drug Safety · 2026 · Same journal
Long-term efficacy and safety of intra-articular corticosteroid injections in patients with knee osteoarthritis · Expert Opinion on Drug Safety · 2026 · Same journal
Lessons from examining the safety of drugs for COVID-19 during pregnancy · Expert Opinion on Drug Safety · 2026 · Same journal